A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

Nl, Harris; Jaffe, ES; Stein, H; Banks, P. M.; Chan, J.K.; Cleary, ML; Delsol, Georges; Peeters, Christoph; Falini, B; Gatter, K C

doi:10.1182/blood.v84.5.1361.bloodjournal8451361

Cited by 307 publications

(234 citation statements)

References 0 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…Mantle cell lymphoma (MCL) is a distinct non‐Hodgkin's lymphoma (NHL) subtype characterized by widespread disease at the time of diagnosis often including bone marrow (BM) involvement, and a poor long‐term survival (1–3). Improved outcome after autologous stem cell transplantation (ASCT) is controversial in uncontrolled studies and register reports (4–8).…”

mentioning

confidence: 99%

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

Andersen¹,

Pedersen²,

Elonen³

et al. 2003

European J of Haematology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

Andersen¹,

Pedersen²,

Elonen³

et al. 2003

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The most widely used system for classifying non‐Hodgkin's lymphomas until the mid‐1990s was the Working Formulation . Although previous diagnostic systems recognized the distinction between T‐cell versus B‐cell lymphoma, it was the development of the REAL classification that was the stimulus for wide‐spread recognition of the significance of diagnosing PTCLs as specific entities . The REAL classification was shown to be clinically relevant, and the system was largely adopted as the WHO classification for lymphomas published in 2001 .…”

Section: Diagnosis Of Peripheral T‐cell Lymphomamentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2017

Armitage

2017

American J Hematol

View full text Add to dashboard Cite

show abstract

“…The most widely used system for classifying non‐Hodgkin's lymphomas until the mid‐1990s was the Working Formulation [3]. Although previous diagnostic systems recognized the distinction between T‐cell versus B‐cell lymphoma [4, 5], it was the development of the REAL classification that was the stimulus for wide spread recognition of the significance of diagnosing PTCLs as specific entities [6]. The REAL classification was shown to be clinically relevant [1] and the system was largely adopted as the WHO classification for lymphomas published in 2001 [7].…”

Section: Diagnosis Of Peripheral T‐cell Lymphomamentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2012 update on diagnosis, risk stratification, and management

Armitage¹

2012

American J Hematol

View full text Add to dashboard Cite

Background: T‐cell lymphomas make up approximately 10–15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia. Diagnosis: The diagnosis of aggressive peripheral T‐cell lymphoma (PTCL) is usually made using the WHO classification. The ability of hematopathologists to reproducibly diagnose aggressive PTCL is lower than for aggressive B‐cell lymphomas, with a range of 72–97% for the aggressive PTCLs. Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography (PET) scans appear to be useful as they are in aggressive B‐cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large‐cell lymphoma—particularly young patients with the anaplastic lymphoma kinase positive subtype. Risk Adapted Therapy: Anaplastic large‐cell lymphoma is the only subgroup to have a good response to a cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)‐like regimen. Angioimmunoblastic T‐cell lymphoma has a prolonged disease‐free survival in only ∼20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL‐not otherwise specified (NOS) is not one disease. Anthracycline containing regimens have disappointing results and a new approach is needed. NK/T‐cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy containing regimens. Enteropathy associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 87:511–519, 2012. © 2012 Wiley Periodicals, Inc.

show abstract

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

Cited by 307 publications

References 0 publications

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

The aggressive peripheral T‐cell lymphomas: 2017

The aggressive peripheral T‐cell lymphomas: 2012 update on diagnosis, risk stratification, and management

Contact Info

Product

Resources

About